Kushal N

Non-steroidal anti-inflammatory drugs (NSAIDs) have wide applicability in management of inflammatory and pain related diseases but limited applicability is characterized by common use and gastrointestinal disturbance. Present study is the trying to come up with sustained release (SR) matrix tablets of NSAIDs using hydrophilic and hydrophobic polymers and correlate the results of in-vitro drug release with the in-vivo pharmacokinetics response. The Ibuprofen drug was selected to be the model, and the direct compression of matrix tablet with HPMC K100M and ethyl cellulose was done. The drug was undergone in-vitro dissolution study using USP-II apparatus with phosphate buffer (pH7.2) and during in-vivo pharmacokinetics testing using healthy volunteers approach crossover study. They came up with a favourable Level An in-vitro/ in-vivo correlation (IVIVC) (R 2= 0.987), showing that the in-vitro kinetics of drug released is a fair representation of the average put on plasma. Sustained release matrix has succeeded in prolonging the duration of drug release to 12 hours and reduced Cmax which contributed to reduction of adverse effects related to a peak. These findings encourage studies into establishing the means of developing SR NSAID formulation to assist in GI toxicity and compliance in patients.

Fast-dissolving tablets (FDTs) are a new type of oral dose form that breaks down quickly in the mouth without water. They are great for kids, older adults, and people who have trouble swallowing. The goal of this study was to improve the formulation of FDTs using paracetamol as a model drug. It did this by using a 3² full factorial Design of Experiments (DoE) to look at how the concentrations of superdisintegrant and binder affected important quality factors like disintegration time, hardness, friability, and drug release. Direct compression was used to make nine formulations (F1–F9), which were then tested using standard pharmacopeial assays. Using ANOVA for statistical analysis, we found that higher quantities of superdisintegrant made the tablets break down faster and release the medicine better, while the amount of binder affected how hard the tablets were. Formulation F7 (6% superdisintegrant, 2% binder) had the best profile of all, with a disintegration time of 25 seconds and 98.3% drug release. The study shows that DoE is a good way to optimize the development of strong, patient-friendly FDTs that work well.